Typically, the starting dose in a Phase 1 trial is too low to show efficacy. For CDR Life, observing immunological activity and biomarker improvement in their very first patient was a rare and remarkable event that provided the first tangible sign their scientific platform could become a real therapeutic.

To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

To bridge the psychological gap between direct patient care and the abstract world of pharma R&D, a former clinician visualizes data points not as numbers, but as the real people he once treated. This mental model keeps the patient as the 'North Star' in all decisions.

While humans are visual, pharma marketers often miss the mark. For oncologists, the most resonant and memorable 'campaign' isn't a branded image but a stark clinical photo—like a brain scan showing a tumor disappearing—because it represents the ultimate patient outcome.

Fibrogen uses its PET imaging agent in Phase 2 not to pre-select patients, but to correlate target expression with treatment response. This data will allow them to enrich their Phase 3 trial with patients most likely to respond, significantly increasing the probability of success.

Rhenium emits both beta particles (for therapy) and gamma rays (for imaging). This unique property allows Plus Therapeutics to see exactly where the drug goes and calculate the precise radiation dose absorbed by the tumor, effectively making every patient a well-controlled, single-subject study.

Perspective Therapeutics' approach is not to target a tumor in a specific organ, but to target a receptor (SSTR2) expressed on various tumors like neuroendocrine, breast, or lung cancer. This receptor-focused strategy creates broader applicability for a single drug, moving beyond traditional organ-based cancer definitions.